Document:

eqh-ex101_13.htm

Exhibit 10.1

 

Execution Version

 

AMENDMENT NO. 3 TO REIMBURSEMENT AGREEMENT

AMENDMENT NO. 3 TO REIMBURSEMENT AGREEMENT, dated as of June 9, 2022 (this “Amendment”), is entered into by and among EQUITABLE HOLDINGS, INC. (f/k/a AXA Equitable Holdings, Inc.), a Delaware corporation (the “Guarantor”), the Subsidiary Account Parties party hereto and COMMERZBANK AG, NEW YORK BRANCH, as LC Issuer. 

PRELIMINARY STATEMENTS:

WHEREAS, the Guarantor, the Subsidiary Account Parties party thereto and the LC Issuer entered into that certain Reimbursement Agreement, dated as of February 16, 2018 (as amended by that certain Amendment No. 1 to Reimbursement Agreement, dated as of March 22, 2021, and Amendment No. 2 to Reimbursement Agreement, dated as of June 25, 2021, and as further amended, amended and restated, supplemented, waived or otherwise modified prior to the date hereof, the “Reimbursement Agreement” and as further amended pursuant to this Amendment, the “Amended Reimbursement Agreement”; capitalized terms not otherwise defined in this Amendment have the same meanings as specified in the Reimbursement Agreement);

 

WHEREAS, the Guarantor has requested that the LC Issuer consent to certain amendments to the Reimbursement Agreement, and the Guarantor, the Subsidiary Account Parties and the LC Issuer have agreed to amend the Reimbursement Agreement as hereinafter set forth.

 

NOW, THEREFORE, in consideration of the premises and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the parties hereto hereby agree as follows:

 

SECTION 1.Amendment to Reimbursement Agreement

. Each of the parties hereto agrees that, effective on the Amendment No. 3 Effective Date (as defined below), Section 2.01(e) of the Reimbursement Agreement is hereby restated in its entirety as follows:

“(e) Extensions to the Commitment Termination Date.  Subject to (i) the absence of any Default or Event of Default that has occurred and is continuing at the time of any extension request and (ii) the written approval being given by the LC Issuer for the relevant extension request and payment of the extension fee as mutually agreed among the Guarantor and the LC Issuer, on or prior to the date that is 30 days prior to each of the first five anniversaries of the Effective Date, upon the Obligors’ request, the Commitment Termination Date will be extended by one additional year, such that if the Obligors exercise each of the five election options, the Commitment Termination Date shall be ten years from the Effective Date.”

SECTION 2.Reference to and Effect on the Credit Documents. 

(a) (a) On and after the Amendment No. 3 Effective Date, each reference in the Reimbursement Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import referring to the Reimbursement Agreement, and each reference in the other Credit Documents to “the Reimbursement Agreement”, “thereunder”, “thereof” or words of like import referring to the “Reimbursement Agreement”, shall mean and be a reference to the Reimbursement Agreement, as amended by this Amendment.  For the avoidance of doubt, this Amendment shall also constitute a Credit Document under the Amended Reimbursement Agreement.

(b)The Reimbursement Agreement, as specifically amended by this Amendment, and the other Credit Documents are, and shall continue to be, in full force and effect, and are hereby in all respects ratified and confirmed. 

1

 

(c)Except as expressly provided herein, the execution, delivery and effectiveness of this Amendment shall not operate as a waiver of any right, power or remedy of the LC Issuer under the Reimbursement Agreement or any other Credit Document, nor shall it constitute a waiver of any provision of the Reimbursement Agreement or any Credit Document.

SECTION 3.Conditions of Effectiveness for Agreement

.  This Amendment shall become effective as of the date (the “Amendment No. 3 Effective Date”) on which the following conditions shall have been satisfied (or waived by the LC Issuer):

 

(a)the LC Issuer shall have received counterparts of this Amendment executed by the Guarantor and the Subsidiary Account Parties party hereto;

 

(b)the representations and warranties contained in the Reimbursement Agreement and in this Amendment shall be true and correct in all material respects on and as of the Amendment No. 3 Effective Date (except that such representations and warranties which are qualified by materiality or Material Adverse Effect shall be true and correct in all respects) (or, if any such representation or warranty is expressly stated to have been made as of a specific date, as of such specific date);

 

(c)no Default or Event of Default shall have occurred and be continuing after giving effect to this Amendment;

 

(d)to the extent invoiced at least two Business Days prior to the Amendment No. 3 Effective Date, all accrued fees and reasonable and documented fees and out-of-pocket expenses payable to the LC Issuer shall have been paid in accordance with Section 5 of this Amendment and Section 8.03 of the Reimbursement Agreement; and

 

(e)receipt by the LC Issuer of any information reasonably requested by the LC Issuer in order to comply with “know your customer” or similar identification requirements of the LC Issuer.

 

By releasing its signature page hereto, the Guarantor shall be deemed to have certified to the LC Issuer that the conditions set forth in clauses (b) and (c) above have been satisfied.

 

SECTION 4.Representations and Warranties

.  The Guarantor hereby represents and warrants to the LC Issuer that:

 

(a)on and as of the date hereof (i) it has all requisite corporate power and authority to enter into and perform its obligations under this Amendment, the Reimbursement Agreement as amended hereby and the other Credit Documents to which it is a party, and (ii) this Amendment has been duly authorized, executed and delivered by it; 

(b)the representations and warranties set forth in Article IV of the Amended Reimbursement Agreement and in the other Credit Documents are true and correct in all material respects on and as of the Amendment No. 3 Effective Date, with the same effect as though made on and as of such date, except to the extent such representations and warranties specifically relate to an earlier date, in which case such representations and warranties shall have been true and correct in all material respects on and as of such earlier date; provided that, in each case, such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and

2

 

(c)this Amendment, and the Reimbursement Agreement as amended hereby, constitute legal, valid and binding obligations of such party, enforceable against it in accordance with their respective terms, subject to (a) the effects of bankruptcy, insolvency, moratorium, reorganization, fraudulent conveyance or other similar laws affecting creditors’ rights generally, (b) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and (c) implied covenants of good faith and fair dealing. 

 

SECTION 5.Costs and Expenses

. The Guarantor agrees that all reasonable, documented and invoiced out-of-pocket expenses incurred by the LC Issuer in connection with the preparation, execution and delivery of this Amendment and the other instruments and documents to be delivered hereunder or in connection herewith are expenses that the Guarantor is required to pay or reimburse pursuant to, and in accordance with, Section 8.03 of the Reimbursement Agreement. 

 

SECTION 6.Execution in Counterparts

. This Amendment may be executed in counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same instrument. Any signature to this Amendment may be delivered by facsimile, electronic mail (including pdf) or any electronic signature complying with the U.S. federal ESIGN Act of 2000 or the New York Electronic Signature and Records Act or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes to the fullest extent permitted by applicable law. For the avoidance of doubt, the foregoing also applies to any amendment, extension or renewal of this Amendment.

 

Each of the parties represents and warrants to the other parties that it has the corporate capacity and authority to execute this Amendment through electronic means and there are no restrictions for doing so in that party’s constitutive documents.

 

SECTION 7.New York Law, Judicial Proceedings and Waiver of Jury Trial

. This Amendment is subject to the provisions of Sections 8.06, 8.07 and 8.10 of the Reimbursement Agreement relating to governing law, waiver of trial by jury and submission to jurisdiction and venue, the provisions which are by this reference incorporated herein in full mutatis mutandis.

SECTION 8.Obligor Affirmation

. Each Subsidiary Account Party party hereto hereby acknowledges and consents to this Amendment. The Guarantor and each Subsidiary Account Party party hereto hereby ratifies and confirms all of its respective obligations and liabilities under the Credit Documents (as amended by this Amendment) to which it is a party and ratifies and confirms that such obligations and liabilities remain in full force and effect.

 

SECTION 9.No Novation

SECTION 10.. This Amendment shall not extinguish the obligations for the payment of money outstanding under the Reimbursement Agreement.  Nothing herein contained shall be construed as a substitution or novation of the obligations outstanding under the Reimbursement Agreement or any instrument securing the same, which shall remain in full force and effect.  Nothing implied in this Amendment or in any other document contemplated hereby shall be construed as a release or other discharge of any of the Obligors under any Credit Document from any of its obligations and liabilities as an Obligor under any of the Credit Documents.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

3

 

 

IN WITNESS WHEREOF, the parties have caused this Amendment No. 3 to Reimbursement Agreement to be executed by their respective authorized officers as of the date first above written. 

GUARANTOR:

 

EQUITABLE HOLDINGS, INC.,

as Guarantor

 

 

By:/s/ Yun Zhag

Name:Yun Zhang
Title:Treasurer

 

 

EQH – Signature Page to Amendment No. 3 to Reimbursement Agreement

 

SUBSIDIARY ACCOUNT PARTIES:

 

 

EQ AZ LIFE RE COMPANY

 

 

 

By:/s/ Yun Zhang

Name:Yun Zhang
Title:Senior Vice President, 

Chief Financial Officer and Treasurer

 

 

EQH – Signature Page to Amendment No. 3 to Reimbursement Agreement

 

LC ISSUER:

 

COMMERZBANK AG, NEW YORK BRANCH, 

as LC Issuer

 

	
 
	
By: /s/ Michael McCarthy
	

Name: Michael McCarthy
Title: Managing Director

 

 

	
 
	
By: /s/ Toan B. Chu
	

Name: Toan B. Chu
Title: Vice President

 

 

 

EQH – Signature Page to Amendment No. 3 to Reimbursement AgreementExhibit 10.1

    

    

    

    

    

    June 10, 2022

     

    Matthew Dyer

    

    

    	Re:	
            Separation Agreement

          

    

    

    Dear Matt:

    

    

    The purpose of this letter agreement (this “Agreement”) is to confirm your resignation from Quantum-Si Incorporated (the “Company”) as its Chief Business Officer
      as of June 15, 2022, and to set forth the terms of your separation from Quantum-Si Incorporated (“Company”). Payment of the Separation Benefits described below is contingent on your agreement to and compliance with the terms of this
      Agreement.  This Agreement shall become effective on the 8th day following your acceptance and non-rescission of it as provided below (the “Effective Date”).

    

    

    	1.	
            Separation of Employment.  You resigned your employment with Company effective as of June 15, 2022 (the “Separation Date”).  You further acknowledge and agree that from and after the Separation Date,
                you hall not represent yourself as an employee or agent of Company. As of the Separation Date, you also resigned from each and every office, position or responsibility in which you served for Company and each of its affiliates, subsidiaries
                or divisions.

          

    

    

    	2.	
            Equity. You
                were granted options to purchase an aggregate of 1,077,872 of the Company’s common stock pursuant to the terms of your Option Agreements (the “Option Agreements”), 119,625 shares of restricted stock and 79,750 restricted share units
                pursuant to the terms of your Restricted Stock Unit Agreement, each pursuant to the terms of Company’s applicable Equity Incentive Plan (the “Plan”). Subject to Section 3, as of the Separation Date, you acknowledge and agree that
                424,677 of options shall be vested and unexercised (the “Vested Options”), 119,625 shares of restricted stock  have vested and previously been distributed to you, and 24,924 restricted share units vested and the underlying shares were
                distributed. 142,114 options had previously been exercised and the remaining 511,081 options and 54,826 restricted share units remain unvested and are forfeited as of the Separation Date.  You acknowledge that you have no right to acquire
                any further stock options, common stock, equity or other interest in Company under the Option Agreements, the Restricted Stock Unit Agreement and/or the Plan and you shall not in the future have any right to acquire any equity or other
                interest in Company.

          

    

    

    	3.	
            Separation Benefits.  In exchange for the promises and release of claims contained herein, the Company shall provide you with the following (the “Separation Benefits”):

          

    

    

    	

          	(a)	
            A lump-sum payment in the amount of $300,000, such amount representing nine (9) months of severance, less all applicable federal, state, local and other legally required or authorized deductions, payable on the Company’s first regularly
              scheduled payroll date following the Effective Date; and

          

    	

          	(b)	
            For the period of July 1, 2022 through March 31, 2023, the Company will pay the costs of your COBRA health insurance if you enroll in COBRA coverage to the extent provided in Section 4 below.

          

     

    

    
      
        

    

    

    

    

    You acknowledge that except for the Separation Benefits and your final wages (each of which shall be paid to you in accordance with Company’s regular
      payroll schedule and applicable law), you are not now and shall not in the future be entitled to any other compensation from Company including, without limitation, other wages, commissions, bonuses, vacation pay, holiday pay, equity, stock, stock
      options, units, carve out, paid time off or any other form of compensation or benefit.  You agree that this payment is something of value and that you are not already entitled to payment of this additional compensation.

    

    

    	4.	
            COBRA Benefits.  Regardless of whether you sign the Agreement, you shall have the right to elect to continue your medical and dental benefits pursuant to the terms and conditions of COBRA. Your eligibility for benefits under COBRA, the amount of
                such benefits, and the terms and conditions of such benefits, shall be determined by COBRA statutory and regulatory guidelines. Subject to your timely election of continuation coverage under COBRA and your signing this Agreement, Company
                will reimburse you or pay on your behalf the monthly premium payable to continue your and your eligible dependents’ participation in Company’s group health plan for the lesser of the period ending March 31, 2023 and the month in which you
                become eligible to participate in a subsequent employer’s group health benefits (the “COBRA Benefit”).  You will notify Company’s Human Resources Department in writing promptly following the date you accept employment with a
                subsequent employer.  If the reimbursement of any COBRA premiums would violate the nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection and Affordable Care Act of 2010, together with the
                Health Care and Education Reconciliation Act of 2010 (collectively, the “Act”) or Section 105(h) of the Internal Revenue Code of 1986 (as amended) (the “Code”), Company-paid premiums will be treated as taxable payments and be
                subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory treatment or taxation under the Act or Section 105(h) of the Code.

          

    

    

    	5.	
            Unemployment Benefits.   By virtue of your separation of employment, you shall be entitled to apply for unemployment benefits. The determination of your eligibility for such benefits (and the amount of
                benefits to which you may be entitled) shall be made by the appropriate state agency pursuant to applicable state law.  Company agrees that it shall not contest any claim for unemployment benefits by you.  Company, of course, shall not be
                required to falsify any information.

          

    

    

    	6.	
            Return of Property, Confidentiality, Non-Disparagement, and Related Matters.  You expressly acknowledge and agree to the following:

          

    

    

    	

          	(a)	
            You have returned to Company all Company documents (and any copies, duplicates, or replicas thereof), and property, including, without limitation, the laptop computer that was provided to you by Company any of its subsidiaries, and their
              respective divisions, affiliates, parents, subsidiaries and related entities (collectively, the “Company Affiliates”) during your employment, and that you will abide by any and all common law and/or statutory obligations relating to
              protection and non-disclosure of the Company’s and Company’s Affiliates’ trade secrets and/or confidential and proprietary documents and information.

          

    

    

    	

          	(b)	
            In the event that you receive an order, subpoena, request, or demand for disclosure of Company’s trade secrets and/or confidential and proprietary documents and information from any court or governmental agency, or from a party to any
              litigation or administrative proceeding, you shall as soon as reasonably possible and prior to disclosure notify the Company of same, in order to provide Company with the opportunity to assert its respective interests in addressing or
              opposing such order, subpoena, request, or demand.

          

    

    

    
      
        

    

    

    

    

    	

          	(c)	
            You agree that all information relating in any way to this Agreement, including the terms and amount of financial consideration provided for in this Agreement, shall be held confidential by you and shall not be publicized or disclosed to
              any person (other than an immediate family member, legal counsel or financial advisor, provided that any such individual to whom disclosure is made agrees to be bound by these confidentiality obligations), business entity or government agency
              (except as mandated by state or federal law).

          

    

    

    	

          	(d)	
            You previously executed a Noncompetition, Confidentiality and Intellectual Property Agreement dated March 14, 2016 (the “Confidentiality Agreement”) and you shall honor and abide by the terms and provisions of the
              Confidentiality Agreement, which shall survive the termination of your employment with Company.

          

    

    

    	

          	(e)	
            You will not make any statements that are disparaging about, or adverse to, the interests or business of Company, any Company Affiliate and their respective officers, directors, employees, and direct or indirect controlling shareholders)
              including, without limitation, any statements that disparage any person, product, service, finances, financial condition, capability or any other aspect of the business of Company or any Company Affiliate (including its officers, directors,
              employees, and direct or indirect shareholders).  “Disparaging” statements are those that, directly or indirectly, impugn the character, honesty, integrity or morality or business acumen or abilities in connection with any aspect of the
              operation of business of the individual or entity being disparaged.  The Company agrees that it will cause the current members of the Company’s Board of Directors to not make any statements that are disparaging about, or adverse to, the
              interests of, you.  Notwithstanding the foregoing, this Section does not prohibit you, the Company or the members of the Company’s Board of Directors from cooperating or testifying truthfully in any internal Company or government inquiry or
              in which you are required to testify pursuant to subpoena or other valid legal process.

          

    

    

    	

          	(f)	
            Your breach of any of the foregoing covenants by you shall constitute a material breach of this Agreement and shall relieve Company of any further obligations hereunder and, in addition to any other legal or equitable remedy available to
              Company, shall entitle Company to recover any Separation Benefits already paid to you pursuant to Section 3 of this Agreement.

          

    

    

    7.          Your Release of
            Claims.

    

    

    	

          	(a)	
            You hereby agree and acknowledge that by signing this Agreement and accepting the Separation Benefits, and for other good and valuable consideration provided for in this Agreement, you are waiving and releasing your right to assert any
              form of legal claim against Company, any of Company Affiliates, their respective successors, predecessors and assigns and each of their respective owners, shareholders, partners, directors, officers, employees, trustees, agents, successors
              and assigns (the “Company Parties”) whatsoever for any alleged action, inaction or circumstance existing or arising from the beginning of time through the Effective Date.  Your waiver and release herein is intended to bar any form of legal
              claim, charge, complaint or any other form of action (jointly referred to as “Claims”) against Company or any of Company Parties seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or
              otherwise), the recovery of any damages or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys’ fees and any other
              costs) against Company or any Company Party, for any alleged action, inaction or circumstance existing or arising through the Effective Date. Without limiting the generality of the foregoing, you specifically waive and release Company and
              Company Parties from any waivable Claim arising from or related to your employment relationship with Company through the Effective Date including, without limitation:

          

     

    
      
        

    

    

     

    	

          	(i)	
            Claims under any Connecticut (or any other state) or federal discrimination, fair employment practices, or other employment related statute, regulation or executive order (as amended through the Effective Date), including but not limited
              to the Age Discrimination in Employment Act (the “ADEA”) and Older Workers Benefit Protection Act (the “OWBPA”) (29 U.S.C. § 621 et seq.), the Civil Rights Acts of 1866 and 1871 and Title VII of the
              Civil Rights Act of 1964 and the Civil Rights Act of 1991 (42 U.S.C. § 2000e et seq.), the Equal Pay Act (29 U.S.C. § 201 et seq.), the Genetic Information
              Non-Discrimination Act (42 U.S.C. §2000ff et seq.), the Uniformed Services Employment and Reemployment Rights Act of 1994 (38 U.S.C. § 4301 et seq.), the Equal
              Pay Act (29 U.S.C. § 201 et seq.), the Lily Ledbetter Fair Pay Act, the Americans with Disabilities Act of 1990 (42 U.S.C. § 12101 et seq.), the Rehabilitation
              Act of 1973, the Connecticut Fair Employment Practices Act, and the Connecticut Equal Pay for Equal Work statute.

          

     

    	

          	(ii)	
            Claims under any Connecticut (or any other state) or federal employment related statute, regulation or executive order (as amended through the Effective Date) relating to wages, hours or any other terms and conditions of employment,
              including but not limited to the Fair Labor Standards Act (29 U.S.C. § 201 et seq.), the National Labor Relations Act (29 U.S.C. § 151 et seq.), the Family and
              Medical Leave Act (29 U.S.C. §2601 et seq.), the Employee Retirement Income Security Act of 1974 (29 U.S.C. § 1000 et seq.), COBRA (29 U.S.C. § 1161 et seq.), the Worker Adjustment and Retraining Notification Act (29 U.S.C. § 2101 et seq.), and any similar Connecticut or
              other state or federal statute, and specifically including Claims related to salary, overtime, commissions, vacation pay, holiday pay, sick leave pay, dismissal pay, bonus pay, severance pay, or retaliation.

          

     

    	

          	(iii)	
            Claims under any Connecticut (or any other state) or federal common law theory, including, without limitation, wrongful discharge, breach of express or implied contract, promissory estoppel, unjust enrichment, breach of a covenant of good
              faith and fair dealing, termination in violation of public policy, defamation, interference with contractual relations, intentional or negligent infliction of emotional distress, promissory estoppel, fraudulent inducement, invasion of
              privacy, misrepresentation, deceit, fraud or negligence or any claim to attorneys’ fees under any applicable statute or common law theory of recovery.

          

     

    	

          	(iv)	
            Claims under any Connecticut (or any other state) or federal statute, regulation, or executive order (as amended through the Effective Date) relating to whistleblower protections, violation of public policy, or any other form of
              retaliation or wrongful termination, including but not limited to the Sarbanes-Oxley Act of 2002, the Connecticut Whistleblower Protection Act and any similar Connecticut or other federal, state or local statute.

          

     

    
      
        

    

    

     

    	

          	(v)	
            Claims under any Company employment, compensation, bonus, benefit, stock option, incentive compensation, restricted stock, restricted stock unit,and/or equity plan, program, policy, practice or agreement, including, without limitation, the
              Option Agreement, The Restricted Stock Unit Agreement, the Plan and your transfer letter with Company dated March 16, 2016.

          

     

    	

          	(vi)	
            Any other Claim arising under other local, state or federal law.

          

     

    You explicitly acknowledge that you have specific rights under the ADEA, which prohibits discrimination on the basis of age, and that the
      releases set forth in this section are intended to release any right that you may have to file a claim against the Company alleging discrimination on the basis of age.

    

    

    	

          	(b)	
            Notwithstanding the foregoing, this Section 7 does not:

          

    

    

    	

          	(i)	
            Release Company or any Company Party from any obligation expressly set forth in this Agreement.

          

    

    

    	

          	(ii)	
            Waive or release any legal claims to vested benefits under Company’s employee benefit plans, including Company’s 401(k) plan.

          

    

    

    	

          	(iii)	
            Waive or release any legal claims which you may not waive or release by law, including obligations under workers’ compensation laws.

          

    

    

    	

          	(iv)	
            Waive or release any legal claims to indemnification under the Indemnification Agreement dated as of June 10, 2021 (the “Indemnification Agreement”) between you and Company or under Company’s director and officers’ insurance policies in
              effect from time to time.

          

    

    

    	

          	(v)	
            Prohibit you from (i) filing a charge with, or participating in or assisting with an investigation or proceeding conducted by, any governmental, regulatory and/or administrative entity or agency (including the Securities Exchange
              Commission, the Equal Employment Opportunity Commission, and/or OSHA); (ii) filing and, including as provided for under Section 21F of the Securities Exchange Act of 1934 (and Regulation 21F thereunder), maintaining the confidentiality of, a
              claim with a governmental, regulatory and/or administrative entity or agency that is responsible for enforcing a law; or (iii) providing truthful information to a governmental, regulatory and/or administrative entity or agency, or court, in
              response to compulsory legal process or as otherwise required by law or legal process or as permitted by Section 21F of the Securities Exchange Act of 1934 (or Regulation 21F thereunder); provided, however, you waive the right to recover any
              personal damages or other personal relief based on any claim, cause of action, demand, lawsuit or similar that is waived pursuant to this Agreement and brought by you or on your behalf by any third party, including as a member of any class or
              collective action, except that you do not waive any right to receive and fully retain any monetary award from a government-administered whistleblower award program for providing information to a government agency, including but not limited to
              damages or relief that may be available to you pursuant to such a program under the Securities Exchange Act of 1934.

          

    

    

    
      
        

    

    

    

    

    	

          	(c)	
            You acknowledge that you may later discover facts in addition to or different from those which you now believe to be true with respect to the matters released in this Agreement.  You, however, agree that you have taken that possibility
              into account in reaching this Agreement, and that the release in this Agreement will remain in effect as a full and complete release for all claims existing as of the date you execute this Agreement, notwithstanding the discovery or existence
              of additional or different facts.  You acknowledge and agree that, but for providing this waiver and release, you would not be receiving the Separation Benefits provided to you under the terms of this Agreement.

          

    

    

    	8.	
            ADEA Review and Revocation Period.  It is the Company’s desire and intent to make certain that you fully understand the provisions and effects of this Agreement. To that end, you have been encouraged and
                given the opportunity to consult with legal counsel for the purpose of reviewing the terms of this Agreement.  Consistent with the provisions of the ADEA and the OWBPA, the Company is providing you with twenty-one (21) days in which to
                consider and accept the terms of this Agreement.  You may rescind your acceptance of this Agreement within seven (7) days after your acceptance of this Agreement. Your acceptance and rescission, respectively, will be effective only upon and
                at the time of hand delivery, or when postmarked and sent by certified mail, return receipt requested, to Lindsay Thompson’s attention at the address of the Company set forth above.

          

    

    

    	9.	
            Waiver of Employment.  You hereby waive and release forever any right or rights you may have to employment with Company and any affiliate thereof at any time in the future and agree not to seek or make application for employment with Company
                or any affiliate thereof.

          

    

    

    	10.	
            Reference Requests.  To the extent Company receives any reference request for you from a prospective employer, Company shall only provide dates of employment and last position held and shall not otherwise characterize or discuss the nature
                of or circumstances surrounding your separation from employment from Company.

          

    

    

    	11.	
            Modification; Waiver; Severability.  No variations or modifications hereof shall be deemed valid unless reduced to writing and signed by the parties hereto. The failure of Company to seek enforcement of any provision of this Agreement in any
                instance or for any period of time shall not be construed as a waiver of such provision or of Company’s right to seek enforcement of such provision in the future.  The provisions of this Agreement are severable, and if for any reason any
                part hereof shall be found to be unenforceable, the remaining provisions shall be enforced in full.

          

    

    

    	12.	
            Choice of Law and Venue; Jury Waiver.   This Agreement shall be deemed to have been made in Connecticut and shall be governed by and construed in accordance with the laws of Connecticut, without giving effect to conflict of law principles.  You
                agree that any action, demand, claim or counterclaim relating to the terms and provisions of this Agreement, or to its breach, shall be commenced in Connecticut in a court of competent jurisdiction, and you further acknowledge that venue
                for such actions shall lie exclusively in Connecticut.  Both parties hereby waive and renounce in advance any right to a trial by jury in connection with such legal action.

          

    

    

    	13.	
            Entire Agreement. You acknowledge and agree that, other than the Confidentiality Agreement, and the Indemnification Agreement which are expressly incorporated herein by reference and stated as surviving the signing of this Agreement, this Agreement
                supersedes any and all prior or contemporaneous oral and written agreements between you and Company and sets forth the entire agreement between you and Company.

          

    

    

    
      
        

    

    

    

    

    	14.	
            Knowing and Voluntary Agreement. By executing this Agreement, you are acknowledging that you have been afforded sufficient time to understand the terms and effects of this Agreement, that your agreements and obligations hereunder are made
                voluntarily, knowingly and without duress, and that neither Company nor its agents or representatives have made any representations inconsistent with the provisions of this Agreement.

          

    

    

    This Agreement may be signed on one or more copies, each of which when signed shall be deemed to be an original, and all of which together shall constitute one and the
      same Agreement.  If the foregoing correctly sets forth our understanding, please sign, date and return the enclosed copy of this Agreement to Lindsay Thompson, Quantum-Si Incorporated, 530 Old Whitfield Street, Guilford, Connecticut 06347.

    

    

    Sincerely,

    

    

    	
            Christian LaPointe

          
	
            Quantum-Si Incorporated

          
	 	 
	
            By:

          	
            /s/ Christian LaPointe

          	 
	 	 
	
            Date:

          	
            June 10, 2022

          	 
	 	 
	
            Agreed and Acknowledged:

          
	 	 
	
            /s/ Matthew Dyer

          	 
	
            Matthew Dyer

          
	
            Date:

          	
            June 10, 2022

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]